Press Releases
Sky Aircraft Maintenance Named Authorized Garmin Aviation Dealer
New Garmin dealership expands avionics modernization capabilities for private and business aircraft operators New Garmin dealership expands avionics modernization capabilities for private and business aircraft operators
Faraday Future Founder and Global CEO YT Jia Shares Weekly Investor Update: Provides New Details on the FF EAI Robotics Education Ecosystem Strategy, Product Line & New EAI Device Launch Happening at Its Los Angeles HQ on June 16
LOS ANGELES--(BUSINESS WIRE)--Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or the “Company”), a California-based global Embodied AI (EAI) ecosystem company, today shared a weekly business update from YT Jia, Founder and Global CEO of FF. “Welcome to issue #59 of the Weekly Report. Today, I want to give everyone a preview of the first launch event of FF's Full-Form EAI Robotics Universe Launch Season, which will take place in just two days. At 5:00 p.m. Pacific...
CARsgen Presents Allogeneic CAR T-cell Products CT0596 and CT1190B at EHA 2026
SHANGHAI, June 14, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces poster presentations for CT0596 (an allogeneic CAR T-cell product targeting BCMA), and CT1190B (an allogeneic CAR T-cell product targeting CD19/CD20) at the 2026 Annual Congress of the European Hematology Association ("EHA"). Data for CT0596 in Relapsed/Refractory Multiple Myeloma and Primary Plasma Cell Leukemia Eight patients, including 6 relapsed/refractory multiple myeloma (R/RMM) and 2 relapsed/refractory primary plasma cell leukemia (R/R pPCL), received CT0596 at the 4.5×10⁸ CAR⁺ T cell dose level...
Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape
The case, originally filed in 2021 by Harbour Antibodies, asserted that Amgen and Teneobio (an Amgen subsidiary) infringed patents protecting Harbour's groundbreaking antibody discovery platform Delaware jury finds infringement willful and patent valid, and awards full $20.2 million in damages; the findings of willful infringement also entitle the Company to petition the judge to treble the award, potentially increasing the award to up to $60.6 million Harbour BioMed will continue to enforce its broader patent portfolio, with a focus on another patent with substantially greater financial implications—potentially representing up to ten times the damages awarded in this case The verdict represents a complete victory for Harbour BioMed, validating the strength of its proprietary transgenic rodent technology and its commitment to protecting scientific innovation CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 14, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced that a jury in the United States District Court for the District of Delaware has returned a decisive verdict in the Company's favor in the patent infringement lawsuit against Amgen Inc., and Teneobio, Inc. (an Amgen subsidiary) (together, "Amgen").The verdict represents a complete victory for Harbour BioMed, validating the strength of its proprietary transgenic rodent technology and its commitment to protecting scientific innovation...
Perseus Mining Increases Share Buy-Back from AUD100M to AUD 150M
Perth, June 15, 2026 (GLOBE NEWSWIRE) -- PERSEUS INCREASES ON-MARKET SHARE BUY-BACK TO A$150MILLION Perth, Western Australia/June 15, 2026/Perseus Mining Limited (ASX/TSX: PRU) is pleased to announce that on June 12, 2026, we have reached A$100 million of the A$100 million on-market share buyback announced in August 2025. Under this buyback, Perseus has purchased 19,077,751 shares at an average price of A$5.24 per share, of shares on issue at notification of the buyback on the 25 November 2025...
Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress
ROCKVILLE, Md. and SUZHOU, China, June 14, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, announced today that seventeen clinical updates from its core assets were presented at the 31st Congress of the European Hematology Association (EHA2026), including eight poster presentations. The presentations featured data from ongoing clinical studies of olverembatinib (HQP1351), the first third-generation BCR-ABL1 inhibitor approved in China, and lisaftoclax (APG-2575), the first approved China-developed Bcl-2 selective inhibitor. The EHA2026 Congress convened in Stockholm, Sweden, from June 11 to 14, 2026...
ComEd Reaches 99% Restoration Following Multi-Day Severe Storm Event
CHICAGO--(BUSINESS WIRE)--ComEd crews have nearly completed the restoration of power to customers impacted by multiple rounds of severe storms that moved through northern Illinois beginning Wednesday afternoon. With 99% of affected customers now restored, crews are in the final stages of repairs and remain committed to completing service restoration for all remaining customers. Multiple bands of severe weather moved through ComEd's northern Illinois service territory on Wednesday and Thursday,...
CEL-SCI Corporation Announces Pricing of Offering
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation announces pricing of offering.
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026
VANCOUVER, British Columbia, June 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today presented new clinical data from the dose-escalation portion of its ongoing Phase 1 study evaluating ZW191, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), at the European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress 2026...
Concept Study Identifies Potential Refining Pathway at Shaakichiuwaanaan to Battery-Grade Lithium Carbonate
Study highlights potential to produce a value-added lithium chemical at site, offering further opportunities to reduce logistics intensity over time and aligning with Canada's and Québec's objectives for domestic processing of critical minerals MONTREAL, June 14, 2026 /PRNewswire/ – June 15, 2026 – Sydney, Australia Highlights Concept study completed evaluating future potential to process spodumene concentrate into a value-added lithium product, directly at the Shaakichiuwaanaan site. Following a structured review of seven processing flowsheet options to produce a "value added" lithium product, the study identified Primero's (NRW Holdings (ASX: NWH) subsidiary "Primero") proprietary ALi atmospheric leach process as the preferred value-added pathway for further study, given: its overall economic potential, strong logistics efficiency benefits and technical risk profile, and its alignment with the Company's sustainability objectives through practicing environmental care in processing and minimizing the Project's environmental footprint...
Oshkosh Defense Highlights Proven, Adaptable Tactical Mobility Solutions for Europe at Eurosatory 2026
PARIS--(BUSINESS WIRE)--As European and allied forces accelerate modernization efforts in response to evolving operational threats, Oshkosh Defense LLC, an Oshkosh Corporation [NYSE: OSK] business, will showcase proven tactical mobility solutions at Eurosatory 2026 designed to support interoperability, distributed operations and future battlefield requirements, without the risk and long development timelines of entirely new vehicle programs. For decades, Oshkosh Defense has supported allied mil...
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
FOSTER CITY, Calif. & WILMINGTON, Del.--(BUSINESS WIRE)--Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in FOP.
Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026
Data show investigational atumelnant drove sustained androgen reductions while enabling lowering of glucocorticoid supplementation to physiologically normal levels in adults with classic CAH New results from the Phase 1b/2a ACTH-dependent Cushing's syndrome trial also presented, showing atumelnant rapidly lowered early morning cortisol and normalized urinary free cortisol levels even at lower dose SAN DIEGO, June 14, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) presented data today from the open-label, Phase 2 congenital adrenal hyperplasia (CAH) adult study of investigational atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist candidate being developed for the treatment of classic CAH and ACTH-dependent Cushing's syndrome. The findings were included in an oral presentation titled “Once Daily Atumelnant (CRN04894) Enables Lowering of Glucocorticoid Doses with Sustained Androgen Reduction in Adults with Congenital Adrenal Hyperplasia” at Endocrine Society's Annual Meeting, ENDO 2026...
OrsoBio Presents Positive Phase 2a Data for LXR Inverse Agonist TLC-2716 in Severe Hypertriglyceridemia and MASLD at ENDO 2026
MENLO PARK, Calif.--(BUSINESS WIRE)-- #ClinicalData--OrsoBio presents positive Phase 2a data for its LXR inverse agonist TLC-2716 in SHTG and MASLD at ENDO 2026.
Elektros Inc. Advances Its Lithium and EV Innovation Strategy as Global Electrification Momentum Accelerates
ELEKTROS INC. (OTC Markets:ELEK) WEST PALM BEACH, FL / ACCESS Newswire / June 14, 2026 / Elektros Inc. (OTC Markets:ELEK), a publicly traded company focused on electrification opportunities, today provided an update on its continued focus on hard rock lithium opportunities, patented electric vehicle charging technology, and long-term strategic initiatives designed to support the rapidly evolving global energy landscape...
Elektros Inc. Strengthens Its Position in Lithium and EV Innovation as the Global Electrification Era Gains Momentum
ELEKTROS INC. (OTC Markets:ELEK) WEST PALM BEACH, FL / ACCESS Newswire / June 14, 2026 / Elektros Inc. (OTC Markets:ELEK), a publicly traded company focused on electrification opportunities, today provided an update on its continued focus on hard rock lithium opportunities, patented electric vehicle charging technology, and long-term strategic initiatives designed to support the rapidly evolving global energy landscape...
Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control
Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms
Elektros Inc. Highlights Long-Term Lithium and EV Innovation Strategy as Global Investors Focus on the Future of Electrification
ELEKTROS INC. (OTC Markets:ELEK) WEST PALM BEACH, FL / ACCESS Newswire / June 14, 2026 / Elektros Inc. (OTC Markets:ELEK), a publicly traded company focused on electrification opportunities, today provided an update on its continued focus on hard rock lithium opportunities, patented electric vehicle charging technology, and long-term strategic initiatives designed to support the rapidly evolving global energy landscape...
Elektros Inc. Embraces the Bright Future of Lithium and EV Innovation as Its Global Electrification Mission Continues to Advance
ELEKTROS INC. (OTC Markets:ELEK) WEST PALM BEACH, FL / ACCESS Newswire / June 14, 2026 / Elektros Inc. (OTC Markets:ELEK), a publicly traded company focused on electrification opportunities, today provided an update on its continued focus on hard rock lithium opportunities, patented electric vehicle charging technology, and long-term strategic initiatives designed to support the rapidly evolving global energy landscape...
AV Introduces TOM 50 RE, a Backpackable UGV for Rapid Reconnaissance and Explosive Ordnance Disposal
OSTFILDERN, Germany--(BUSINESS WIRE)---- $AVAV #AVAV--AeroVironment, Inc. (“AV”), a global leader in autonomous systems, today announced the launch of TOM 50 RE, a compact, backpackable uncrewed ground vehicle (UGV) developed by its wholly owned subsidiary Telerob. Designed for mobile exploration, mission-accompanying reconnaissance, explosive threat disposal, and operational support, TOM 50 RE enables dismounted forces, explosive ordnance disposal (EOD) teams, and special operations units—including SWAT—to ra...
Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting
HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the presentation of long-term results from the Phase 2 study of barzolvolimab in a flash talk session at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul, Türkiye. The data presented demonstrated that barzolvolimab treatment results in rapid, significant, and durable improvements in angioedema in patients with chronic spontaneous urticaria (CSU) refractory to antihistamines. These results were sustained off-treatment, seven months after completion of barzolvolimab dosing (Week 76). The data continue to demonstrate barzolvolimab's potential to shift the goal of CSU treatment from symptom control to disease modification and further support the ongoing Phase 3 trials of barzolvolimab in CSU...
Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)
– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension –
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026
– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants –
Tradr to Ring Opening Bell at Cboe to Celebrate SpaceX ETF Launches
Tradr ETFs will ring Cboe's Opening Bell on June 15 to celebrate the launch of SPCM and SPCG, ETFs providing 200% leveraged long and short exposure to the newly public SpaceX stock. Firm to commemorate the launch of SPCM and SPCG from the center of the world's largest options trading floor NEW YORK, June 14, 2026 /PRNewswire/ -- Tradr ETFs, a provider of ETFs designed for sophisticated investors and professional traders, today announced that its team will ring the Opening Bell at Cboe Global Markets at 8:30 am on Monday, June 15, 2026...
Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today presented positive results from the Phase 1 healthy participant study of CDX-622, a novel, bispecific antibody that targets soluble SCF and TSLP, at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul, Türkiye. Data demonstrated that CDX-622 induced rapid, durable, dose-dependent reductions in serum tryptase, indicative of mast cell depletion, and was well-tolerated at all dose levels. Building on Celldex's leadership in mast cell science, the data also demonstrated that neutralizing soluble stem cell factor (SCF) enables the potential for meaningful mast cell inhibition and depletion without impacting other KIT-dependent functions. CDX-622 is currently being studied in a Phase 1b proof of mechanism study in mild to moderate asthma to assess the impact of dual neutralization of SCF and TSLP...
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 2026
GENEVA--(BUSINESS WIRE)--OM Pharma Unveils the Largest Multi-Country Real-World Evidence Study on Broncho Vaxom (OM 85) for RTI Prevention at EAACI 2026.
Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
INDIANAPOLIS, June 14, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-322 clinical trial of Jaypirca (pirtobrutinib), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, plus venetoclax and rituximab versus venetoclax and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). The study met its primary endpoint of independent review committee (IRC)-assessed progression-free survival (PFS), demonstrating that the addition of pirtobrutinib to a two-year venetoclax plus rituximab regimen reduced the risk of disease progression or death by 45% (HR=0.55 [95% CI, 0.40-0.75]; p=0.0001)...
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
BRIDGEWATER, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced first clinical proof-of-concept data for LB2501, its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The results are being presented today in a late-breaking session at the European Hematology Association (EHA) 2026 Congress (Abstract #LB5006)...
Elektros Inc. Ignites New Momentum Across Lithium, EV Innovation, and Critical Minerals as the Global Electrification Era Accelerates
ELEKTROS INC. (OTC Markets:ELEK) WEST PALM BEACH, FL / ACCESS Newswire / June 13, 2026 / Elektros Inc. (OTC Markets:ELEK), a publicly traded company focused on electrification opportunities, today provided an update regarding its continued focus on hard rock lithium opportunities, patented electric vehicle charging technology, and strategic initiatives supporting the future of transportation, energy infrastructure, and critical minerals...
Elektros Inc. Powers Ahead as Global Demand for Lithium, EV Innovation, and Critical Minerals Creates New Opportunities for Electrification
ELEKTROS INC. (OTC Markets:ELEK) WEST PALM BEACH, FL / ACCESS Newswire / June 13, 2026 / Elektros Inc. (OTC Markets:ELEK), a publicly traded company focused on electrification opportunities, today provided an update regarding its continued focus on hard rock lithium opportunities, patented electric vehicle charging technology, and strategic initiatives supporting the future of transportation, energy infrastructure, and critical minerals...
Elektros Inc. Accelerates Its Vision for Lithium, EV Innovation, and the Future of Electrification
ELEKTROS INC. (OTC Markets:ELEK) WEST PALM BEACH, FL / ACCESS Newswire / June 13, 2026 / Elektros Inc. (OTC Markets:ELEK), a publicly traded company focused on electrification opportunities, today provided an update on its continued focus on hard rock lithium opportunities, patented electric vehicle charging technology, and long-term strategic initiatives designed to support the rapidly evolving global energy landscape...
ICE Box Claims Evaluated: Personal Document Storage System for Organization & Secure Protection in Case of Emergencies
ICE Box organizes vital records, estate planning documents, and emergency files in one fireproof box with a 32GB USB stick and expert-developed checklist.
Powering the Future of Electrification
Elektros Inc. Continues Advancing Lithium Opportunities, EV Charging Innovation, and Strategic Growth Initiatives Positioned to Capitalize on Expanding Global Demand for Critical Minerals, Energy Infrastructure, and Electric Vehicles ELEKTROS INC. (OTC PINK:ELEK) WEST PALM BEACH, FL / ACCESS Newswire / June 13, 2026 / Elektros Inc. (OTC PINK:ELEK) today provided an update regarding its ongoing focus on hard rock lithium opportunities, patented electric vehicle charging technology, and continued efforts to advance its long-term strategic initiatives in support of the evolving electrification marketplace...
XM Announces Enhanced Trading Conditions and Opportunities for Global Traders - Featuring Partner Code 274PQ
TORONTO, June 14, 2026 (GLOBE NEWSWIRE) -- As participation in online financial markets continues to expand worldwide, trading platforms are increasingly focused on technology, education, and user accessibility. XM, an international online trading platform, has announced ongoing developments across its platform ecosystem while highlighting the availability of Partner Code 274PQ for eligible new users during the registration process...
Air Canada and the IAMAW Reach Tentative Agreement on New Contract
MONTRÉAL, June 13, 2026 (GLOBE NEWSWIRE) -- Air Canada today said it has reached a tentative collective agreement with the International Association of Machinists and Aerospace Workers (IAMAW) representing more than 11,000 Air Canada employees in Maintenance, Cabin Services, Airport Airside Operations, Cargo, Finance and Clerical...
Cycclone, Inc. Announces Agreement in Principle for the Acquisition of AI Robotics Company
NEW YORK CITY, NY / ACCESS Newswire / June 13, 2026 / Cycclone, Inc. (OTCID:CYCL) today acknowledges reaching an agreement in principle to acquire an AI Robotics design, develop and manufacturing company under the newly formed division, Cycclone Ai Robotics. Recently an agreement in principle has been reached for Cycclone to acquire an American AI Robotics company based in California...
Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism
COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the three-and-a-half-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems – CNS, kidney, small intestine, and bone – as demonstrated by improved quality of life and normalized and stable urine calcium, serum calcium, serum phosphate, and bone mineral density. These benefits were sustained while enabling independence from conventional therapy with active vitamin D and calcium...
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new data from two studies evaluating epcoritamab, a T-cell engaging antibody administered subcutaneously, in the first-line (1L) treatment of patients with diffuse large B-cell lymphoma (DLBCL) who may have limited treatment options due to advanced age or multiple health conditions. Results from the Phase 2 EPCORE DLBCL-3 study showed an overall response rate (ORR) of 67% and a complete response (CR) rate of 58% wi...
Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting
INDIANAPOLIS, June 13, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data from the Phase 1 AJX-101 study showing that its investigational type II JAK2 inhibitor (AJ1-11095) demonstrated an encouraging safety profile and promising clinical activity in patients with myelofibrosis who have been failed by a type I JAK2 inhibitor. This first-in-class type II JAK2 inhibitor was designed to selectively bind the type II conformation of the JAK2 kinase in order to potentially provide greater efficacy than existing therapies and a novel treatment option for patients who become resistant to type I JAK2 inhibitors...
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #EHA2026--New Positive Data Showed INCA033989 Achieved Rapid, Robust & Sustained Clinical & Molecular Responses and Was Well Tolerated in Patients with MF & ET.
AI Infrastructure News: How Investors Can Participate in the Cloud GPU Leasing Boom and Generate Passive Income in 2026
AI GPU Rental is offering short-term ways to invest in AI computing power. New users can also get up to $128 in free credits to try it. AI GPU Rental is offering short-term ways to invest in AI computing power. New users can also get up to $128 in free credits to try it.
Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease
Mitapivat demonstrated statistically significant improvement in hemoglobin response compared with placebo, with rapid onset and durable effects New analyses showed patients in mitapivat arm had clinically meaningful reduction in transfusion burden compared with placebo Patients in mitapivat arm who achieved hemoglobin response had clinically meaningful benefits across measures of sickle cell pain crises, fatigue, and other patient-reported outcomes Mitapivat was well-tolerated, with a safety profile consistent with previous trials of mitapivat in sickle cell disease Company to host investor conference call and webcast today at 9:00 a.m. ET (3:00 p.m...
Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
-- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures -- -- Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS --
Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
CAMBRIDGE, Mass., June 13, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today presented additional positive results from the global Phase 3 HAELO clinical trial of lonvo-z (formerly NTLA-2002) for hereditary angioedema (HAE) in a late-breaking oral presentation at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026 in Istanbul, Türkiye. Results from the trial were simultaneously published in the New England Journal of Medicine. The presentation and publication can be accessed from the Scientific Publications and Presentations section of intelliatx.com...
New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma
BEERSE, BELGIUM, June 13, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced results from the investigational Phase 3 MonumenTAL-3 study.1 The results showed that TALVEY (talquetamab), a GPRC5D bispecific antibody, in combination with daratumumab with or without pomalidomide demonstrated significant reduction in the risk of disease progression or death of up to 72.0%, and clinically meaningful reduction of up to 53.0% in the risk of death, compared to the standard regimen of daratumumab, pomalidomide, and dexamethasone (DPd) in patients with relapsed or refractory multiple myeloma (RRMM).1 Results showed a progression-free survival (PFS) rate of up to 81.3% versus standard of care (51.2%) and an overall survival (OS) rate of up to 89.2% versus standard of care (79.1%) at 24 months...
New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma
STOCKHOLM, June 13, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced results from the investigational Phase 3 MonumenTAL-3 study showing that TALVEY (talquetamab-tgvs), a GPRC5D bispecific antibody, in combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) with or without pomalidomide demonstrated significant reduction in the risk of disease progression or death of up to 72% and clinically meaningful reduction of up to 53% in the risk of death compared to the standard regimen of DARZALEX FASPRO, pomalidomide, and dexamethasone (DPd) in patients with relapsed/refractory multiple myeloma (RRMM).1 Results showed a progression-free survival (PFS) rate of up to 81.3% versus standard of care (51.2%) and an overall survival (OS) rate of up to 89.2% versus standard of care (79.1%) at 24 months...
Dr. Reddy's Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #Bosulif--Dr. Reddy's Laboratories Ltd. announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif in the United States.
Results from Incyte's Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #EHA2026--Results from Incyte's frontMIND Trial of Tafasitamab (Monjuvi/Minjuvi) Combination at the 2026 EHA Plenary Showed Prolonged Progression Free Survival.
Hitch Open Ping-Pong Embodied (HOPE) AI Challenge Joins the 2026 World Humanoid Robot Games, Seeding Advanced Physical AI Against Human Performance
Created by Intelligent Racing Foundation and jointly operated with Beao Group, HOPE AI Challenge brings world's top teams to spark next AI breakthrough
BTU Additional Details Regarding Recent Acquisition
VANCOUVER, BC / ACCESS Newswire / June 12, 2026 / BTU METALS CORP. ("BTU" or the "Company") (TSXV:BTU)(OTCQB:BTUMF) is announces that on June 3rd, 2026 the Company announced that it had entered into a definitive agreement to acquire a 100% interest in the Dixie East Block 3 Project (the "Project" or the "Property"), located approximately 6 kilometres east of the Kinross-owned Great Bear Project in the eastern part of the Red Lake District, Ontario...
Defiance ETFs Announces Temporary Trading Halt of the Defiance Daily 2X Space ETF (SPCL) on Cboe BZX Exchange, Inc.
MIAMI, June 12, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs, a leader in thematic and leveraged exchange-traded funds, today announced that trading in shares of the Defiance Daily 2X Space ETF (Cboe BZX: SPCL) was temporarily halted by Cboe BZX Exchange, Inc. (the “Exchange”).
Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
DALLAS, June 12, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc. (Nasdaq: RKDA), a producer and marketer of innovative wellness products, announced today the closing of its previously announced private placement priced at-the-market under Nasdaq rules for the purchase and sale of 3,883,496 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 preferred investment options to purchase up to an aggregate of 3,883,496 shares of common stock and Series A-2 preferred investment options to purchase up to an aggregate of 3,883,496 shares of common stock at a purchase price of $1.03 per share of common stock (or pre-funded warrant in lieu thereof) and associated preferred investment options...
Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1
SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced the completion of its rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant. Tinlarebant is an investigational, once-daily oral therapy for the treatment of Stargardt disease type 1 (STGD1), a rare, inherited retinal disease caused by mutations in the ABCA4 gene that leads to progressive and irreversible vision loss. STGD1 affects an estimated 53,000 people in the U.S. alone, and there are currently no approved treatment options for the disease...
ComEd Continues Power Restoration Following Two Powerful Storms
CHICAGO--(BUSINESS WIRE)--ComEd crews continue restoring power to customers impacted by multiple rounds of severe storms that moved through northern Illinois beginning Wednesday afternoon. With the most volatile weather now past the region, crews are focused on completing repairs and restoring service to remaining pockets of customers affected by storm damage. Multiple bands of severe weather brought intense rain, frequent lightning and high wind gusts, causing significant damage to ComEd's pow...
Republic Technologies Inc. Provides Bi-Weekly Update On Annual Filings
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $DOCKF #Blockchain--Republic Technologies Inc. (CSE: DOCT) (FSE: 7FM0) (OTCQB: DOCKF) (“Republic” or the "Company") today provided an update with respect to its previously announced management cease trade order ("MCTO") in connection with the Company's filing of its audited annual financial statements (the " Financial Statements") and management discussion and analysis (the "MD&A") for the financial year ended December 31, 2025, and the applicable CEO and CFO certi...
ROMA Green Finance Establishes Dedicated Artificial Intelligence and High-Performance Computing Infrastructure Investment Vertical
New vertical extends ROMA's sustainable-finance mandate into energy-efficient, behind-the-meter-powered digital infrastructure; Company is evaluating a pipeline of distributed, sub-50 MW AI/HPC investment opportunities, subject to diligence, definitive documentation, and board approval.
Battery X Metals Appoints Automotive Industry Professional from Canadian Subsidiary of One of the World's Leading Premium Automobile Manufacturers, Headquartered in Munich, Germany, to its Advisory Board to Advance Commercialization of Its Patent-Pending Lithium-Ion Battery Rebalancing Machine
News Release Highlights: Battery X Metals expands its Advisory Board with the appointment of Mr. Zachary Funk, an automotive industry professional with experience at the Canadian division of one of the world's leading premium automobile manufacturers, further strengthening the Company's commercialization capabilities and industry engagement initiatives as it advances deployment of its patent-pending lithium-ion battery rebalancing technology...
NU E Power Corp. Files 2026 First Quarter Results
Calgary, Alberta--(Newsfile Corp. - June 12, 2026) - NU E Power Corp. (CSE: NUE) ("NUE" or the "Company") announces that it has filed its unaudited interim condensed consolidated financial statements and management's discussion and analysis ("MD&A") for the first quarter of 2026. The interim filings are available under the Company's profile on SEDAR+ at www.sedarplus.ca and on the Company's website at www.nu-energy.ca...
OpenText to Create 400 Jobs with €105 Million Investment in Cork and Galway to Expand Agentic AI and Sovereign Cloud in Europe
Taoiseach Micheál Martin TD and CEO of IDA Ireland Michael Lohan join OpenText to announce new Cork Centre of Excellence for EMEA Investment marks the largest in Ireland by a Canadian-headquartered technology company, advancing R&D in agentic AI, sovereign cloud and cyber resilience for EMEA clients DUBLIN, June 12, 2026 /PRNewswire/ -- OpenText™ (NASDAQ/TSX: OTEX), a Waterloo, Ontario, Canada headquartered global leader in data management for enterprise AI, today announced a €105 million investment that will create 400 new jobs across the company's sites in Ireland over the next three years. The commitment, which doubles OpenText's investment in Ireland, will significantly expand the company's agentic AI, cybersecurity, sovereign cloud, and digital operations capabilities in service of European, Middle East & African (EMEA) economies and public sectors...
TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's TRUQAP (capivasertib) in combination with abiraterone and prednisone has been approved in the US as the first and only targeted treatment for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive (mAPMN/S) prostate cancer, previously referred to as metastatic hormone-sensitive prostate cancer (mHSPC), as detected by a US Food and Drug Administration (FDA)-authorized test.1 The approval by the US FDA was bas...
Rio Silver Announces Results of Annual General Meeting
VANCOUVER, British Columbia , June 12, 2026 (GLOBE NEWSWIRE) -- Rio Silver Inc. (“Rio Silver” or the “Company”) (TSX.V: RYO) (OTC: RYOOF), announces shareholder approval for all matters at the AGM.
Prime Drink Group Announces Private Placement and Agreed Resolution with Creditors
MONTREAL, June 12, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that it is proceeding with a non-brokered private placement offering of units of the Company (the “Units”) to raise minimum gross proceeds of $1,200,000 and maximum gross proceeds of $2,200,000 (the “Unit Offering”)...
CORRECTION -- Leverage Shares by Themes Launches 2X Long and -2X Short SpaceX ETFs with 0.75% Fee to Meet Unprecedented Retail Demand
GREENWICH, Conn., June 12, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Themes ETF Trust, please note that in the first paragraph, the commencement of trading for the new ETFs has been corrected to June 15 at 9:30 AM ET, instead of 4:00 AM ET.
Whirlpool Announces Cash Tender Offer Early Results
BENTON HARBOR, Mich., June 12, 2026 /PRNewswire/ -- Whirlpool Corporation (NYSE: WHR) ("Whirlpool" or the "Company") is releasing early results as of 5:00 p.m.
CleanTech Issues Clarification Regarding Qualified Person Disclosure
Vancouver, British Columbia--(Newsfile Corp. - June 12, 2026) - CleanTech Vanadium Mining Corp. (TSXV: CTV) (OTCQB: CTVFF) ("CleanTech" or the "Company") wishes to clarify that the Qualified Person disclosure contained in its news release dated June 12, 2026 entitled "CleanTech to Focus on Fluorspar and Sell Robinson-Lasher Zinc-Germanium-Gallium Project to Silver Elephant" was included in error. The news release did not contain scientific or technical disclosure requiring review by a qualified person under National Instrument 43-101...
Caprock Announces Proposed Private Placement
Toronto, Ontario--(Newsfile Corp. - June 12, 2026) - Caprock Mining Corp. (CSE: CAPR) ("Caprock" or the "Company") is pleased to announce a proposed non-brokered private placement offering of up to 6,000,000 flow-through shares (the "FT Shares") at a price of $0.10 per FT Share for aggregate gross proceeds of up to $600,000 (the "Offering"). The Company may, in its discretion and subject to the approval of the Canadian Securities Exchange (the "CSE"), increase the size of the Offering...
New Zealand Energy Corp. Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - June 12, 2026) - New Zealand Energy Corp. (TSXV: NZ) ("NZEC" or the "Company") reports that further to the Company's news releases regarding the issuance of a management cease trade order by the British Columbia Securities Commission in connection with the delay in filing its annual disclosure documents (collectively, the "Annual Filings") for the year ended December 31, 2025 (the "MCTO News Release"), the Company confirms that work on the required documents is continuing and progressing. The Company continues to work closely with its independent reserves evaluator and external auditors to complete the reserves evaluation process and finalize the audited annual consolidated financial statements as expeditiously as possible...
Caprock Announces Consistent High-Grade Intercepts from the Final Three Deep Drill Holes at Destiny, Including 8.32 g/t Au over 2.6m
Toronto, Ontario--(Newsfile Corp. - June 12, 2026) - Caprock Mining Corp. (CSE: CAPR) ("Caprock", or the "Company") is pleased to announce high-grade assay results for the final three drill holes from the recently concluded deep drilling campaign at its flagship Destiny gold property ("Destiny", or the "Property", or the "Project"), located near Val d'Or, Quebec. Key Assay Highlights from the Final 3 Deep Drill Holes: DES-26-184W1: Intersected 8.32 g/t Au over 2.6m and 6.43 g/t Au over 1.8m...
PreveCeutical Closes Second Tranche of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - June 12, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news releases dated May 12, 2026 and April 22, 2026, it has closed a second tranche (the "Second Tranche") of its previously announced non-brokered private placement (the "Offering"), which Second Tranche consisted of the issuance of 9,800,000 units (each, a "Unit") of the Company at a price of $0.025 per Unit for gross aggregate proceeds of $245,000. The Company closed an initial tranche (the "Initial Tranche") on May 12, 2026, consisting of the issuance of 13,600,000 Units for gross proceeds of $340,000...
BlackRock ESG Capital Allocation Term Trust (ECAT) Announces Certified Results of 2026 Annual Shareholder Meeting
NEW YORK--(BUSINESS WIRE)---- $ECAT--BlackRock ESG Capital Allocation Term Trust (NYSE: ECAT) Announces Certified Results of 2026 Annual Shareholder Meeting.
Capitan Silver Announces Results of Annual General and Special Meeting of Shareholders
All Matters Overwhelmingly Approved Vancouver, British Columbia--(Newsfile Corp. - June 12, 2026) - Capitan Silver Corp. (TSXV: CAPT) (OTCQX: CAPTF) ("Capitan" or the "Company") is pleased to announce the results of its annual general and special meeting of shareholders (the "Meeting") held earlier today. A total of 65,819,634 common shares of the Company were voted at the Meeting, representing approximately 51.13% of the total number of common shares of the Company issued and outstanding...
Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds
$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants SEATTLE, June 12, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced the closing of its previously announced registered direct offering of 1,363,637 shares (the "Shares") of its common stock, par value $0.18 per share ("Common Stock") (or common stock equivalents in lieu thereof), Series A warrants to purchase up to 1,363,637 shares of Common Stock and short-term Series B warrants to purchase up to 1,363,637 shares of Common Stock (such warrants, collectively, the "Series Warrants") and accompanying Series Warrants. The Series Warrants are exercisable six months following the date of issuance...
Avicanna Announces Closing of Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, June 12, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce that it has closed a non-brokered private placement offering of 4,000,014 units of the Company (“Units”) at a price of $0.15 per Unit for aggregate gross proceeds of $600,002.1 (“Offering”)...
Heartland Express, Inc. Declares Regular Quarterly Dividend
NORTH LIBERTY, Iowa, June 12, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Heartland Express, Inc. (Nasdaq: HTLD) announced today the declaration of a regular quarterly cash dividend. The $0.02 per share dividend will be paid on July 6, 2026, to shareholders of record at the close of business on June 23, 2026...
Gencor Releases Second Quarter Fiscal 2026 Results
ORLANDO, Fla., June 12, 2026 (GLOBE NEWSWIRE) -- Gencor Industries, Inc. (the “Company” or “Gencor”) (NYSE American: GENC) announced today net revenue for the quarter ended March 31, 2026 was $33,799,000 compared with $38,204,000 net revenue for the quarter ended March 31, 2025.
Traws Pharma Provides Regulatory Update on Influenza Program
NEWTOWN, Pa., June 12, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral threats, today announced that the planned test of tivoxavir marboxil (TXM) in a Phase 2a human influenza challenge study has been deferred due to a negative review of the program by the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA)...
Emperor Announces Adoption of Semi-Annual Reporting
Edmonton, Alberta--(Newsfile Corp. - June 12, 2026) - Emperor Metals Inc. (CSE: AUOZ) (OTCQB: EMAUF) (FSE: 9NH) ("Emperor") announces the adoption of semi-annual financial reporting ("SAR"). This news release is being filed pursuant to Coordinated Blanket Order 51 - 933 Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers ("CBO 51-933")...
Canagold Resources Ltd. Announces Voting Results from Annual General Meeting
Vancouver, British Columbia--(Newsfile Corp. - June 12, 2026) - Canagold Resources Ltd. (TSX: CCM) (OTCQB: CRCUF) (FSE: CANA) (the "Company") announces that at its annual general meeting of shareholders held on June 12, 2026 (the "Meeting"), all directors listed in the Information Circular dated May 11, 2026 were elected...
BlackRock Announces Product Updates
NEW YORK--(BUSINESS WIRE)--BlackRock has one of the most comprehensive investment platforms in the industry, providing investors with choice to meet their individual needs. Investors continue to turn to BlackRock to unlock the full potential of their portfolios, as evidenced by nearly $2 trillion of net inflows in the past five years globally.1 As we evolve our global investment platform, we also continually assess how our funds are meeting investors' investment objectives and the needs of our...
Casa Minerals Inc. Provides MCTO Update
Vancouver, British Columbia--(Newsfile Corp. - June 12, 2026) - Casa Minerals Inc. (TSXV: CASA) (OTCQB: CASXF) (FSE: 0CM) (the "Company" or "Casa") is providing an update to its news release dated June 8, 2026, wherein the Company announced that it expected the management cease trade order that was granted on May 1, 2026 (the "MCTO") to be revoked shortly after completing the filing of: (1) the audited annual financial statements for the year ended December 31, 2025, (2) the management discussion and analysis and, (3) related Chief Executive Officer and Chief Financial Officer certificates. However, since the news release, the Company has encountered difficulties with completing its interim financial report and related management discussion and analysis for the period ended March 31, 2026 (the "Q1 Financials")...
BioNxt Announces Non-Brokered Private Placement of Units Pursuant to the Listed Issuer Exemption
Not for distribution to U.S. newswire services or for dissemination in the United States. VANCOUVER, BC / ACCESS Newswire / June 12, 2026 / BioNxt Solutions Inc. (CSE:BNXT)(FSE:4XT) (the "Company" or "BioNxt") is pleased to announce a non-brokered private placement of units of the Company ("Units") at a price of $0.33 per Unit, for maximum aggregate gross proceeds of up to approximately $2,000,000 (the "Offering") pursuant to the Listed Issuer Financing ("LIFE") exemption available under Part 5A of National Instrument 45-106 - Prospectus Exemptions ("NI 45-106")...
TechCreate Group Ltd. Issues Statement Addressing NYSE Delisting Procedure
SINGAPORE--(BUSINESS WIRE)--TechCreate Group Ltd. (NYSE American: TCGL) (“TechCreate” or the “Company”), a technology consultancy and advanced software solutions provider specializing in payment solutions, cybersecurity, and digital services, provided a statement in light of NYSE American LLC's (“NYSE American”) announcement that it intends to commence proceedings to delist TechCreate's Class A ordinary shares from the NYSE American stock exchange and, in the interim, to continue to suspend the...
Rocket Doctor Grants Stock Options and RSUs
Vancouver, BC, June 12, 2026 (GLOBE NEWSWIRE) -- Rocket Doctor AI Inc. ( CSE: AIDR , OTC: AIRDF , Frankfurt: 939) (“Rocket Doctor AI”) has granted an aggregate 47,013 stock options, exercisable at $0.71 per share and valid for a term of three years, and an aggregate 514,801 restricted share units, valid for a term between one to three years, to consultants and employees of the Company and its subsidiaries. The stock options and restricted share units are issued pursuant to the Company's share compensation plans and are subject to a statutory hold period of four months and one day from issuance, in addition to vesting provisions. Additionally, and further to the Company's news release dated July 18, 2025, the Company has extended the marketing services provided by 45 Degrees, Inc. (“45 Degrees”) and Investment Publishing LLC (“Investment Publishing”) to provide digital marketing and investor awareness services until September 30, 2026. No additional compensation shall be payable to 45 Degrees or Investment Publishing for the additional services provided...
Federal Signal Provides Update on Streator, Illinois Facility; Announces Signing of Definitive Agreement to Acquire Western Technology, Expanding its Presence in Portable Industrial Signaling Solutions for Hazardous Environments
DOWNERS GROVE, Ill., June 12, 2026 /PRNewswire/ -- Federal Signal Corporation (NYSE: FSS) (the "Company"), a leader in environmental and safety solutions, today provided an update on its manufacturing facility in Streator, Illinois following a tornado that impacted the area on June 11, 2026.
KBRA Assigns Preliminary Ratings to OBX 2026-AHC2 Trust
NEW YORK--(BUSINESS WIRE)-- #creditratingagency--KBRA assigns preliminary ratings to 65 classes of mortgage pass-through notes from OBX 2026-AHC2 Trust, a prime agency-eligible RMBS transaction sponsored by Onslow Bay Financial LLC, that is fully originated and serviced by AmeriHome Mortgage Company, LLC (AmeriHome). This transaction is comprised of 599 residential mortgages with an aggregate unpaid principal balance (UPB) of approximately $340.0 million as of the June 1, 2026 cut-off date. The underlying collateral...
Leverage Shares by Themes Launches 2X Long and -2X Short SpaceX ETFs with 0.75% Fee to Meet Unprecedented Retail Demand
GREENWICH, Conn., June 12, 2026 (GLOBE NEWSWIRE) -- Following the historic IPO of SpaceX, Leverage Shares by Themes today announced the launch of the Leverage Shares 2X Long SpaceX Daily ETF (CBOE: SPCH) and the Leverage Shares 2X Short SpaceX Daily ETF (CBOE: SSPC). Both funds begin trading on June 15 on Cboe; and are expected to be available for trading as early as 4:00 AM EST...
AISIX Solutions Inc. Provides Status Report of Annual Financial Statements and MD&A
Vancouver, British Columbia--(Newsfile Corp. - June 12, 2026) - AISIX Solutions Inc. (TSXV: AISX) ("AISIX" or the "Company") provides this bi-weekly default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Management Cease Trade Orders ("NP 12-203"). The Company previously announced on May 1, 2026 that the British Columbia Securities Commission had issued a management cease trade order ("MCTO") further to the Company's application to the applicable securities regulatory authorities in Canada on the basis that the Company's audited annual financial statements, management's discussion and analysis and the applicable CEO and CFO certificates for the financial year ended December 31, 2025 (collectively, the "Annual Filings") would not be filed by the applicable filing deadline of April 30, 2026 (the "Default Announcement")...
Conquest Resources Reports Results of Annual and Special Meeting of Shareholders
Toronto, Ontario--(Newsfile Corp. - June 12, 2026) - Conquest Resources Limited (TSXV: CQR) ("Conquest" or the "Company") reports that it held its Annual and Special Meeting of Shareholders on Thursday, June 11, 2026 at which all resolutions were approved and passed. ELECTION OF DIRECTORS All of the nominees for election as director, John F...
Edgemont Provides Updates on Transaction with Laiva Gold
Vancouver, British Columbia--(Newsfile Corp. - June 12, 2026) - Edgemont Gold Corp. (CSE: EDGM) ("Edgemont") wishes to provide an update on certain matters relating to its reverse takeover transaction (the "Transaction") with Laiva Gold Inc. ("Laiva"). Due to strong investor interest, Laiva will be completing an additional financing round prior to completion of the Transaction (the "Financing")...
Hydro One seeks approval from the Ontario Energy Board to build the Durham Kawartha Power Line
The new line is expected to support growth, reliability and local priorities in central and eastern Ontario TORONTO, June 12, 2026 /PRNewswire/ - Today, Hydro One Networks Inc. (Hydro One) announced it has filed a leave-to-construct application with the Ontario Energy Board (OEB) to seek approval to construct the Durham Kawartha Power Line. The new approximately 55-kilometre double-circuit, 230-kilovolt transmission line will be built between Clarington Transformer Station (TS) in the Municipality of Clarington, and Dobbin TS in Peterborough County...
Nutrien Cautions Investors Regarding Ocehan LLC's Below Market “Mini-Tender” Offer
SASKATOON, Saskatchewan--(BUSINESS WIRE)--Nutrien Ltd. (TSX and NYSE: NTR) has received notice of an unsolicited “mini-tender” offer made by Ocehan LLC (“Ocehan”) to purchase up to 100,000 Nutrien common shares, or approximately 0.02% of Nutrien's outstanding shares, at a price of C$70.20 per share. The offering price represents a discount of 24.91% and 26.13%, respectively, to the closing prices of Nutrien shares on the Toronto Stock Exchange and New York Stock Exchange on May 8, 2026, the las...
XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange
CALGARY, Alberta, June 12, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that the Company has elected to voluntarily delist its common shares from the TSX Venture Exchange (“TSXV”). The Company will provide additional information on timing for the completion of the delisting of its common shares in a separate press release...
Lotus Tech Announces Operational and Earnings Reporting Updates
NEW YORK, June 12, 2026 (GLOBE NEWSWIRE) -- Lotus Technology Inc. (Nasdaq: LOT) (“Lotus Tech” or the “Company”), a leading global intelligent and luxury mobility provider, today provided an update on recent developments and announced the temporary suspension of the publication of earnings releases for the first quarter and third quarter of fiscal year 2026...